Clinical trials: Hyperlipidemias
Atherosclerotic Cardiovascular Disease
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).
- Trial name
- VICTORION-2P (NCT05030428)
- Testing
- Inclisiran sodium 300 mg
- Where
- 983 sites in United States, Argentina and 48 more
- Volunteers
- 17,004 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Disease Prevention, Cardiometabolic Diseases
Preventative Screening and Health Coaching in a Food Insecure Population
The goal of this longitudinal study is to investigate the role of virtual health coaching on mitigation of cardiometabolic disease risk in an underserved, food insecure population.
- Conditions
- Cardiovascular Disease Prevention, Cardiometabolic Diseases, Cardiovascular Risk Factor, Cardiovascular Risk Score
- Trial name
- HEALTHCOACH (NCT06907524)
- Testing
- Longitudinal, Individualized Health Coaching
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Rush University Medical Center
Hypertension, Hyperglycemia
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
The objective of this study is to pilot a multifaceted, optimized intervention for metabolic syndrome (MetS) in emergency department patients to establish feasibility.
- Conditions
- Hypertension, Hyperglycemia, Dyslipidemia, Metabolic Syndrome
- Trial name
- METS (NCT07119658)
- Testing
- Composite intervention to address MetS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
This is a multi-center, randomized, double-blind, placebo-controlled phase III clinical study evaluating the efficacy and safety of IBI306 monotherapy in Chinese Paricipants with non-familial hypercholesterolemia and mixed…
- Trial name
- NCT07473960
- Testing
- IBI306
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Coronary Artery Disease, Hyperlipidaemia
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CT
This randomized controlled study will evaluate whether icosapent ethyl (IPE) can improve and stabilize high-risk coronary plaques in patients receiving stable low-density lipoprotein cholesterol (LDL-C)-lowering therapy.
- Conditions
- Coronary Artery Disease, Hyperlipidaemia, Hypertriglyceridaemia, Coronary Atherosclerosis
- Trial name
- IPE-NaF (NCT07762755)
- Testing
- icosapent ethyl (IPE), Standard LDL-C-Lowering Therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- China National Center for Cardiovascular Diseases
Lipoprotein Disorder
A Study of DII235 in Adults With Elevated Lipoprotein(a)
The main purpose of this study is to determine the safety and efficacy of DII235 in adults with elevated lipoprotein(a).
- Trial name
- NCT07235046
- Testing
- DII235, Saline
- Where
- 63 sites in United States, China and 2 more
- Volunteers
- 234 people
- Sponsor
- Novartis Pharmaceuticals
Insulinemic Response, Type 2 Diabetes (Adult Onset)
Impact of High-Oleic Palm Oil Consumption on Cardiovascular Biomarkers in Adults in Bogotá
This randomized clinical trial aims to evaluate the effects of refined high-oleic palm oil consumption on cardiovascular risk biomarkers and insulin resistance in healthy adults.
- Conditions
- Insulinemic Response, Type 2 Diabetes (Adult Onset), Hyperglycaemia (Diabetic), Hyperlipidaemia
- Trial name
- EDCHOPA-CRB (NCT07748559)
- Testing
- High-oleic palm oil
- Where
- Colombia
- Volunteers
- 52 people
- Sponsor
- Ruby Alejandra Villamil
Hyperlipidaemia, Liver Biomarkers
Therapeutic Effects of Cinnamon-Enriched Cookies on Hypercholesterolemia and Liver Function
Cinnamon-enriched cookies were developed and evaluated for their sensory acceptability and potential as a functional food for adults with hyperlipidemia.
- Conditions
- Hyperlipidaemia, Liver Biomarkers, Weight Change
- Trial name
- NCT07740473
- Testing
- Treatment group T1
- Where
- Pakistan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Lahore
Hypercholesterolemia and Hyperlipidemia
Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers
In order to improve the medication convenience and compliance of patients and facilitates in the long-term control of disease condition, it is planned to reduced the number of injections to one per administration.
- Trial name
- NCT06837077
- Testing
- SHR-1209 single-site subcutaneous injection, SHR-1209 multiple-site subcutaneous injections
- Where
- China
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hyperlipidemias
Effect of Omega-3 Supplementation on Fasting Triglycerides During Lifestyle Intervention in Adults With Mild-to-moderate Hypertriglyceridemia
Patients with hyperlipidemia will be allocated to the intervention or control group randomly. Participants of the intervention group will be provided with Omega-3 PUFA, while participants of the control group will be provided…
- Trial name
- NCT05015348
- Testing
- Omega-3 PUFA supplementation
- Where
- China
- Volunteers
- 127 people
- Sponsor
- Peking Union Medical College Hospital
Atherosclerotic Cardiovascular Disease
VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
VictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an innovative therapy with the potential to help bridge care gaps in historically understudied and undertreated populations by leveraging…
- Trial name
- V-INCLUSION (NCT06249165)
- Testing
- Inclisiran
- Where
- 23 sites in United States
- Volunteers
- 130 people
- Sponsor
- Duke University
Hyperlipidemia, Diabete Type 2
A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B
To evaluate the pharmacokinetic interaction and the safety of AD-236A and AD-236B in healthy adult volunteers
- Trial name
- NCT07730567
- Testing
- Treatment A(AD-236A), Treatment B(AD-236B), Treatment C(AD-236A+AD-236B)
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Familial Hypercholesterolemia - Homozygous
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to <12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein…
- Trial name
- ORION-19 (NCT06597006)
- Testing
- Inclisiran
- Where
- 19 sites in United States, Austria and 9 more
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Diseases, Myocardial Infarction
Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coordination
This pragmatic clinical trial embedded in an accountable care organization will determine the comparative effectiveness of two approaches for assigning care coordinators to older adults at risk for cardiovascular outcomes.
- Conditions
- Cardiovascular Diseases, Myocardial Infarction, Atrial Fibrillation, Diabetes Mellitus
- Trial name
- NCT05820295
- Testing
- Care coordination delivered based on perceived need, Care coordination delivered based on usual care (e.g. discharge from hospital)
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Weill Medical College of Cornell University
Hyperlipidemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0167 in Healthy Participants
This study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SAL0167 following single and multiple dose administration in healthy participants.
- Trial name
- NCT07722299
- Testing
- SAL0167 group
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Mixed Hyperlipidemia
A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia
This is a randomized, double-blind, placebo-parallel, multicenter phase II clinical trial to evaluate the efficacy and safety of SYH2070 injection in participants with mixed hyperlipidemia.
- Trial name
- NCT07695597
- Testing
- SYH2070
- Where
- China
- Volunteers
- 240 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Hypertriglyceridemic Acute Pancreatitis, Acute Pancreatitis, Hypertriglyceridemia-induced
Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCT
Background: Hypertriglyceridemia-associated acute pancreatitis (HTG-AP) has become the second most common cause of acute pancreatitis in China, accounting for up to 42.4% of cases, with high recurrence rates and substantial…
- Conditions
- Hypertriglyceridemic Acute Pancreatitis, Acute Pancreatitis, Hypertriglyceridemia-induced, Hyperlipidemia
- Trial name
- NCT07720232
- Testing
- Live Combined Bacillus subtilis and Enterococcus faecium Enteric-coated Capsules (LCBE), Standard Care (in control arm)
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Jianyin Zhou
Acute Coronary Syndrome, Hyperlipidemias
PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI
The primary objective was to evaluate the effect of PCSK 9 Inhibitor (initiated within 4 h from PCI for the culprit lesion) with high-intensity statin treatment, compared to placebo with high-intensity statin treatment, on…
- Conditions
- Acute Coronary Syndrome, Hyperlipidemias, Percutaneous Coronary Intervention, Cardiovascular Events
- Trial name
- SHAWN (NCT05457582)
- Testing
- PCSK 9 Inhibitor plus high-intensity statin
- Where
- China
- Volunteers
- 1,212 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Diabete Mellitus, Prediabetes
Amelioration of Lipid Profile Through Date Cider-vinegar Along With 5:2 Intermittent Fasting
A common metabolic abnormality in hyperglycemic individuals, dyslipidemia is strongly linked to an increased risk of cardiovascular illness.
- Conditions
- Diabete Mellitus, Prediabetes, Hyperlipidemia
- Trial name
- NCT07710898
- Testing
- Control Group (T 0 ), Experimental Group (T 1 ), Experimental Group (T 2 )
- Where
- Pakistan
- Volunteers
- 108 people
- Sponsor
- University of Lahore
Hyperlipidemia
Tafolecimab in Hyperlipidemia: A Study of Different Dosing Intervals
This is a prospective, observational cohort study. Patients will be assigned to either the Q2W or Q3W group based on the treating physician's clinical decision, not by randomization.
- Trial name
- NCT07712042
- Testing
- Tafolecimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Mei Gao